相似文献
1
Characterization of binding of raltegravir to plasma proteins.
Antimicrob Agents Chemother. 2013 Oct;57(10):5147-50. doi: 10.1128/AAC.00625-13. Epub 2013 Jul 15.
2
Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
PLoS One. 2012;7(7):e40223. doi: 10.1371/journal.pone.0040223. Epub 2012 Jul 2.
3
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
Antimicrob Agents Chemother. 2010 Feb;54(2):614-9. doi: 10.1128/AAC.00797-09. Epub 2009 Dec 7.
4
Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.
J Mol Recognit. 2013 Sep;26(9):383-401. doi: 10.1002/jmr.2277.
5
Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.
Br J Clin Pharmacol. 1990 Jan;29(1):9-18. doi: 10.1111/j.1365-2125.1990.tb03596.x.
6
Factors affecting serum protein binding of cocaine in humans.
J Pharmacol Exp Ther. 1995 Nov;275(2):605-10.
7
Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein.
Br J Clin Pharmacol. 1984 Oct;18(4):487-93. doi: 10.1111/j.1365-2125.1984.tb02496.x.
8
Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.
Antimicrob Agents Chemother. 2012 Dec;56(12):6132-6. doi: 10.1128/AAC.00942-12. Epub 2012 Sep 10.
9
Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.
HIV Med. 2006 Mar;7(2):122-8. doi: 10.1111/j.1468-1293.2006.00356.x.
10
Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria.
J Pharm Pharmacol. 1992 Oct;44(10):806-11. doi: 10.1111/j.2042-7158.1992.tb03210.x.
引用本文的文献
1
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1533. doi: 10.3390/ph15121533.
2
Pharmacokinetic drug interactions of integrase strand transfer inhibitors.
Curr Res Pharmacol Drug Discov. 2021 Aug 8;2:100044. doi: 10.1016/j.crphar.2021.100044. eCollection 2021.
3
Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.
Toxicol Sci. 2021 Nov 24;184(2):191-203. doi: 10.1093/toxsci/kfab112.
4
Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00895-20.
5
Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00759-20.
6
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
Clin Pharmacokinet. 2019 Mar;58(3):309-323. doi: 10.1007/s40262-018-0684-z.
7
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Clin Pharmacokinet. 2017 Jan;56(1):25-40. doi: 10.1007/s40262-016-0424-1.
本文引用的文献
1
Intracellular drug concentrations.
Clin Pharmacol Ther. 2013 Mar;93(3):263-6. doi: 10.1038/clpt.2012.240. Epub 2012 Dec 11.
2
Divalent metals and pH alter raltegravir disposition in vitro.
Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6. doi: 10.1128/AAC.06407-11. Epub 2012 Mar 26.
3
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):450-7. doi: 10.1097/QAI.0b013e3182364c67.
4
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
Clin Pharmacokinet. 2011 Apr;50(4):229-44. doi: 10.2165/11584570-000000000-00000.
5
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
AIDS. 2010 Oct 23;24(16):2581-3. doi: 10.1097/qad.0b013e32833d89fa.
6
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.
7
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000.
8
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.
9
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.
10
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1057-69. doi: 10.1016/j.jchromb.2009.02.057. Epub 2009 Feb 28.
Zotero 插件